Olaparib in Unresectable/Metastatic Melanoma With BRCA1/2

NCT05482074 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Principal Investigator left the institute

Conditions

Recurrent Metastatic Melanoma
Cutaneous Melanoma
Mucosal Melanoma
Uveal Melanoma

Interventions

DRUG: Olaparib

Sponsor

Dana-Farber Cancer Institute

Collaborators

[object Object]